Literature DB >> 35635330

The mitochondrial pyruvate carrier at the crossroads of intermediary metabolism.

Nicole K H Yiew1, Brian N Finck1.   

Abstract

Pyruvate metabolism, a central nexus of carbon homeostasis, is an evolutionarily conserved process and aberrant pyruvate metabolism is associated with and contributes to numerous human metabolic disorders including diabetes, cancer, and heart disease. As a product of glycolysis, pyruvate is primarily generated in the cytosol before being transported into the mitochondrion for further metabolism. Pyruvate entry into the mitochondrial matrix is a critical step for efficient generation of reducing equivalents and ATP and for the biosynthesis of glucose, fatty acids, and amino acids from pyruvate. However, for many years, the identity of the carrier protein(s) that transported pyruvate into the mitochondrial matrix remained a mystery. In 2012, the molecular-genetic identification of the mitochondrial pyruvate carrier (MPC), a heterodimeric complex composed of protein subunits MPC1 and MPC2, enabled studies that shed light on the many metabolic and physiological processes regulated by pyruvate metabolism. A better understanding of the mechanisms regulating pyruvate transport and the processes affected by pyruvate metabolism may enable novel therapeutics to modulate mitochondrial pyruvate flux to treat a variety of disorders. Herein, we review our current knowledge of the MPC, discuss recent advances in the understanding of mitochondrial pyruvate metabolism in various tissue and cell types, and address some of the outstanding questions relevant to this field.

Entities:  

Keywords:  adipose tissue; heart; liver; mitochondrion; pyruvate

Mesh:

Substances:

Year:  2022        PMID: 35635330      PMCID: PMC9273276          DOI: 10.1152/ajpendo.00074.2022

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   5.900


  204 in total

Review 1.  Dysregulated pH: a perfect storm for cancer progression.

Authors:  Bradley A Webb; Michael Chimenti; Matthew P Jacobson; Diane L Barber
Journal:  Nat Rev Cancer       Date:  2011-08-11       Impact factor: 60.716

2.  An immunochemical study of the pyruvate dehydrogenase deficit in Alzheimer's disease brain.

Authors:  K F Sheu; Y T Kim; J P Blass; M E Weksler
Journal:  Ann Neurol       Date:  1985-05       Impact factor: 10.422

3.  Systemic pyruvate administration markedly reduces neuronal death and cognitive impairment in a rat model of Alzheimer's disease.

Authors:  Xiaonan Wang; Xuejun Hu; Yang Yang; Toshihiro Takata; Takashi Sakurai
Journal:  Exp Neurol       Date:  2015-06-07       Impact factor: 5.330

4.  Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis.

Authors:  Kyle S McCommis; Wesley T Hodges; Elizabeth M Brunt; Ilke Nalbantoglu; William G McDonald; Christopher Holley; Hideji Fujiwara; Jean E Schaffer; Jerry R Colca; Brian N Finck
Journal:  Hepatology       Date:  2017-03-30       Impact factor: 17.425

5.  Dietary energy substrates reverse early neuronal hyperactivity in a mouse model of Alzheimer's disease.

Authors:  Misha Zilberter; Anton Ivanov; Sofya Ziyatdinova; Marat Mukhtarov; Anton Malkov; Alan Alpár; Giuseppe Tortoriello; Catherine H Botting; Lívia Fülöp; Alex A Osypov; Asla Pitkänen; Heikki Tanila; Tibor Harkany; Yuri Zilberter
Journal:  J Neurochem       Date:  2013-01-10       Impact factor: 5.372

Review 6.  Regulation of intracellular pH in the myocardium; relevance to pathology.

Authors:  P A Poole-Wilson
Journal:  Mol Cell Biochem       Date:  1989-09-07       Impact factor: 3.396

7.  Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina.

Authors:  Jianhai Du; Whitney M Cleghorn; Laura Contreras; Ken Lindsay; Austin M Rountree; Andrei O Chertov; Sally J Turner; Ayse Sahaboglu; Jonathan Linton; Martin Sadilek; Jorgina Satrústegui; Ian R Sweet; François Paquet-Durand; James B Hurley
Journal:  J Biol Chem       Date:  2013-11-01       Impact factor: 5.157

Review 8.  The Warburg effect: 80 years on.

Authors:  Michelle Potter; Emma Newport; Karl J Morten
Journal:  Biochem Soc Trans       Date:  2016-10-15       Impact factor: 5.407

Review 9.  The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment.

Authors:  Yaxin Huang; Guohui Sun; Xiaodong Sun; Feifan Li; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

Review 10.  Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis.

Authors:  Olga Khomich; Alexander V Ivanov; Birke Bartosch
Journal:  Cells       Date:  2019-12-20       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.